Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.85 EUR | -0.84% | -1.25% | -7.06% |
Mar. 14 | Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024 | CI |
Mar. 14 | Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024 |
Sales 2024 * | 8.15M 8.71M | Sales 2025 * | 11.95M 12.77M | Capitalization | 335M 358M |
---|---|---|---|---|---|
Net income 2024 * | -14M -14.97M | Net income 2025 * | -18M -19.24M | EV / Sales 2024 * | 39.6 x |
Net cash position 2024 * | 11.6M 12.4M | Net Debt 2025 * | 7M 7.48M | EV / Sales 2025 * | 28.6 x |
P/E ratio 2024 * |
-23.9
x | P/E ratio 2025 * |
-18.2
x | Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 43.38% |
Latest transcript on Hyloris Pharmaceuticals SA
1 day | -0.42% | ||
1 week | -0.83% | ||
Current month | +3.93% | ||
1 month | +5.31% | ||
3 months | -7.39% | ||
6 months | -7.75% | ||
Current year | -6.67% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Jacobsen
FOU | Founder | 50 | 11-12-31 |
Stijn van Rompay
FOU | Founder | 48 | 11-12-31 |
Director of Finance/CFO | 53 | 21-09-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carolyn Myers
BRD | Director/Board Member | 66 | 19-12-31 |
James Gale
BRD | Director/Board Member | 74 | 19-12-31 |
Leon van Rompay
BRD | Director/Board Member | 75 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 11.85 | -0.84% | 3 406 |
24-04-24 | 11.95 | +2.14% | 4,475 |
24-04-23 | 11.7 | -2.09% | 7,424 |
24-04-22 | 11.95 | -0.42% | 10,433 |
24-04-19 | 12 | 0.00% | 14,706 |
Real-time Euronext Bruxelles, April 25, 2024 at 06:53 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.67% | 358M | |
+22.85% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+12.36% | 219B | |
+6.47% | 199B | |
-10.06% | 196B | |
-8.75% | 149B | |
-5.21% | 146B |
- Stock Market
- Equities
- HYL Stock